NewsAlzheimer's diseaseMay 20, 2026
Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's
Risen Pharma has initiated a Phase 2 clinical trial for RP902, aimed at treating Mild Cognitive Impairment associated with Alzheimer's Disease. This development could significantly impact the Alzheimer's treatment landscape.
Dr. Yuki Tanaka
